12:00 AM
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Fluocinolone acetonide intravitreal implan: Phase III started

pSivida began a single-blind, sham-controlled, international Phase III trial to evaluate 0.18 mg fluocinolone acetonide intravitreal implant in 120 patients with recurrent non-infectious uveitis affecting the posterior segment of the eye with or without anterior uveitis.

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >